918 related articles for article (PubMed ID: 15804725)
41. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Chaturvedi RK; Shukla S; Seth K; Chauhan S; Sinha C; Shukla Y; Agrawal AK
Neurobiol Dis; 2006 May; 22(2):421-34. PubMed ID: 16480889
[TBL] [Abstract][Full Text] [Related]
42. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
Lee EY; Lee JE; Park JH; Shin IC; Koh HC
Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
[TBL] [Abstract][Full Text] [Related]
43. Chronic nicotine treatment differentially regulates substance P and tyrosine hydroxylase immunoreactivity in substantia nigra ipsilateral to a unilateral lesion.
Janson AM; Fuxe K
Exp Neurol; 1997 Aug; 146(2):575-86. PubMed ID: 9270071
[TBL] [Abstract][Full Text] [Related]
44. In vivo characterization of somatodendritic dopamine release in the substantia nigra of 6-hydroxydopamine-lesioned rats.
Sarre S; Yuan H; Jonkers N; Van Hemelrijck A; Ebinger G; Michotte Y
J Neurochem; 2004 Jul; 90(1):29-39. PubMed ID: 15198664
[TBL] [Abstract][Full Text] [Related]
45. Consequences of partial and severe dopaminergic lesion on basal ganglia oscillatory activity and akinesia.
Tseng KY; Kargieman L; Gacio S; Riquelme LA; Murer MG
Eur J Neurosci; 2005 Nov; 22(10):2579-86. PubMed ID: 16307600
[TBL] [Abstract][Full Text] [Related]
46. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
[TBL] [Abstract][Full Text] [Related]
47. Sparing of behavior and basal extracellular dopamine after 6-hydroxydopamine lesions of the nigrostriatal pathway in rats exposed to a prelesion sensitizing regimen of amphetamine.
Moroz IA; Peciña S; Schallert T; Stewart J
Exp Neurol; 2004 Sep; 189(1):78-93. PubMed ID: 15296838
[TBL] [Abstract][Full Text] [Related]
48. Neurorescue effects of VEGF on a rat model of Parkinson's disease.
Yasuhara T; Shingo T; Muraoka K; Kameda M; Agari T; Wen Ji Y; Hayase H; Hamada H; Borlongan CV; Date I
Brain Res; 2005 Aug; 1053(1-2):10-8. PubMed ID: 16045899
[TBL] [Abstract][Full Text] [Related]
49. Dopaminergic innervation of substance P-containing striatal neurons by fetal nigral grafts: an ultrastructural double-labeling immunocytochemical study.
Mendez I; Elisevich K; Flumerfelt B
J Comp Neurol; 1991 Jun; 308(1):66-78. PubMed ID: 1714923
[TBL] [Abstract][Full Text] [Related]
50. Neuroprotective and neurotrophic effect of apomorphine in the striatal 6-OHDA-lesion rat model of Parkinson's disease.
Yuan H; Sarre S; Ebinger G; Michotte Y
Brain Res; 2004 Nov; 1026(1):95-107. PubMed ID: 15476701
[TBL] [Abstract][Full Text] [Related]
51. Suppressive effect of L-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine.
Blunt SB; Jenner P; Marsden CD
Mov Disord; 1993 Apr; 8(2):129-33. PubMed ID: 8097279
[TBL] [Abstract][Full Text] [Related]
52. NMDA receptors mediate an early up-regulation of brain-derived neurotrophic factor expression in substantia nigra in a rat model of presymptomatic Parkinson's disease.
Bustos G; Abarca J; Bustos V; Riquelme E; Noriega V; Moya C; Campusano J
J Neurosci Res; 2009 Aug; 87(10):2308-18. PubMed ID: 19326433
[TBL] [Abstract][Full Text] [Related]
53. Relation between rotation in the 6-OHDA lesioned rat and dopamine loss in striatal and substantia nigra subregions.
Olds ME; Jacques DB; Kopyov O
Synapse; 2006 Jun; 59(8):532-44. PubMed ID: 16565974
[TBL] [Abstract][Full Text] [Related]
54. Loss of striatal DA innervation increases striatal trophic activity directed at DA neurons in culture.
Carvey PM; Lin DH; Faselis CJ; Notermann JK; Ling ZD
Exp Neurol; 1996 Aug; 140(2):184-97. PubMed ID: 8690061
[TBL] [Abstract][Full Text] [Related]
55. Differential astroglial activation in 6-hydroxydopamine models of Parkinson's disease.
Henning J; Strauss U; Wree A; Gimsa J; Rolfs A; Benecke R; Gimsa U
Neurosci Res; 2008 Dec; 62(4):246-53. PubMed ID: 18824050
[TBL] [Abstract][Full Text] [Related]
56. Deprenyl induces GFAP immunoreactivity in the intact and injured dopaminergic nigrostriatal system but fails to counteract axotomy-induced degenerative changes.
Revuelta M; Venero JL; Machado A; Cano J
Glia; 1997 Oct; 21(2):204-16. PubMed ID: 9336235
[TBL] [Abstract][Full Text] [Related]
57. A nitric oxide synthase inhibitor decreases 6-hydroxydopamine effects on tyrosine hydroxylase and neuronal nitric oxide synthase in the rat nigrostriatal pathway.
Gomes MZ; Raisman-Vozari R; Del Bel EA
Brain Res; 2008 Apr; 1203():160-9. PubMed ID: 18313645
[TBL] [Abstract][Full Text] [Related]
58. Regulation of GAP-43 protein and mRNA in nigrostriatal dopaminergic neurons after the partial destruction of dopaminergic terminals with intrastriatal 6-hydroxydopamine.
Iwata SI; Nomoto M; Fukuda T
Synapse; 2001 Jan; 39(1):16-22. PubMed ID: 11071705
[TBL] [Abstract][Full Text] [Related]
59. Mesencephalic neural stem (progenitor) cells develop to dopaminergic neurons more strongly in dopamine-depleted striatum than in intact striatum.
Nishino H; Hida H; Takei N; Kumazaki M; Nakajima K; Baba H
Exp Neurol; 2000 Jul; 164(1):209-14. PubMed ID: 10877931
[TBL] [Abstract][Full Text] [Related]
60. Glial gene expression during aging in rat striatum and in long-term responses to 6-OHDA lesions.
Pasinetti GM; Hassler M; Stone D; Finch CE
Synapse; 1999 Mar; 31(4):278-84. PubMed ID: 10051108
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
